[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.220.238. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
The Cutting Edge: Challenges in Medical and Surgical Therapies
June 2012

Angiosarcoma of the Scalp Successfully Treated With a Single Therapy of Sorafenib

Author Affiliations
 

SECTION EDITOR: EDWARD W. COWEN, MD, MHSc; ASSISTANT SECTION EDITORS: MURAD ALAM, MD; RUTH ANN VLEUGELS, MD

Arch Dermatol. 2012;148(6):683-685. doi:10.1001/archdermatol.2011.2819

Angiosarcoma (AS) of the scalp is a rare and aggressive neoplasm with one of the worst prognoses among malignant skin tumors. The overall 5-year survival rate is less than 30%.1 Specific treatment guidelines are absent, and treatment options include surgical excision, radiation therapy, chemotherapy (CT), and biological therapy such as recombinant interleukin 2 (rIL-2). Surgical excision with negative margins combined with CT is the most successful strategy for improving the prospect for survival.2,3

First Page Preview View Large
First page PDF preview
First page PDF preview
×